OpenAI CEO Sam Altman says a man used ChatGPT to create a personalised cancer vaccine for his dog, h
openai
| Source: Mastodon | Original article
OpenAI chief executive Sam Altman highlighted a striking case this week: an Australian pet owner with no formal scientific training used ChatGPT and other generative‑AI tools to design a bespoke mRNA vaccine for his dog’s aggressive cancer. The owner fed the model data from the animal’s biopsy, tumor‑genomics reports and publicly available mRNA‑vaccine protocols, then asked ChatGPT to outline a sequence that would target the identified mutations. With guidance from the AI, he partnered with a contract‑research laboratory, synthesized the custom RNA strand and administered the vaccine under veterinary supervision. Early reports suggest the dog’s tumors have regressed, though the treatment remains experimental and has not undergone formal regulatory approval.
Altman seized on the episode to illustrate both the promise and perils of powerful language models. “If a layperson can piece together a personalized cancer vaccine for a pet, imagine what could be done in medicine, agriculture or bio‑security,” he told reporters, adding that OpenAI is “working on safeguards” to curb misuse while preserving the technology’s creative potential. The story arrives amid mounting scrutiny of AI’s role in biomedical research, where recent advances in protein‑folding and drug‑discovery models have already accelerated pipelines in pharma.
The episode raises immediate questions for regulators and the scientific community. Will health authorities require AI‑generated therapeutic designs to be vetted before any clinical use? How will OpenAI and other model providers monitor prompts that venture into high‑risk domains such as gene editing or vaccine design? Observers will watch for any policy updates from the U.S. Food and Drug Administration, the European Medicines Agency and OpenAI’s own usage‑policy revisions. The incident also foreshadows a likely surge in DIY bio‑hacking projects, prompting a broader debate on where the line should be drawn between open innovation and public safety.
Sources
Back to AIPULSEN